Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs. [PDF]
J Neurosci, 2016 Burnett CJ, Krashes MJ.
europepmc +1 more source
Molecular Oncology, EarlyView.Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Biotechnological Synthesis of the Designer Drug Metabolite 4'-Hydroxymethyl- -pyrrolidinohexanophenone in Fission Yeast Heterologously Expressing Human Cytochrome P450 2D6--A Versatile Alternative to Multistep Chemical Synthesis [PDF]
, 2009 Frank T. Peters +6 more
openalex +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. [PDF]
J Cheminform, 2014 Krasowski MD, Ekins S.
europepmc +1 more source
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs. [PDF]
ACS Chem Neurosci, 2015 Chen X +6 more
europepmc +1 more source
Identification and characterization of new designer drug 4-fluoro-PV9 and α-PHP in the seized materials [PDF]
, 2015 Milena Majchrzak +4 more
openalex +1 more source